Robert E. Claypoole - 09 Jan 2026 Form 4 Insider Report for Bioventus Inc. (BVS)

Role
President and CEO, Director
Signature
/s/ Anthony D'Adamio, Attorney-in-Fact
Issuer symbol
BVS
Transactions as of
09 Jan 2026
Net transactions value
-$334,988
Form type
4
Filing time
13 Jan 2026, 17:30:00 UTC
Previous filing
14 Jan 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Claypoole Robert E President and CEO, Director 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM /s/ Anthony D'Adamio, Attorney-in-Fact 13 Jan 2026 0002005474

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BVS Class A Common Stock Options Exercise $0 +93,750 +144% $0.000000 158,714 09 Jan 2026 Direct
transaction BVS Class A Common Stock Tax liability $334,988 -41,717 -26% $8.03 116,997 09 Jan 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BVS Restricted Stock Units Options Exercise $0 -93,750 -33% $0.000000 187,500 09 Jan 2026 Class A Common Stock 93,750 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2 The RSUs shall vest in four equal installments on each of the first four anniversaries of January 10, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date.